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Background: Cystic fibrosis (CF) lung microbiota consists of diverse species which are pathogens or opportunists
or have unknown pathogenicity. Here we report the full characterization of a recently described multidrug resistant
bacterium, Microbacterium yannicii, isolated from a CF patient who previously underwent lung transplantation.
Results: Our strain PS01 (CSUR-P191) is an aerobic, rod shaped, non-motile, yellow pigmented, gram positive,
oxidase negative and catalase positive bacterial isolate. Full length 16S rRNA gene sequence showed 98.8%
similarity with Microbacterium yannicii G72T type strain, which was previously isolated from Arabidopsis thaliana. The
genome size is 3.95Mb, with an average G+C content of 69.5%. In silico DNA-DNA hybridization analysis between
our Microbacterium yannicii PS01isolate in comparison with Microbacterium testaceum StLB037 and Microbacterium
laevaniformans OR221 genomes revealed very weak relationship with only 28% and 25% genome coverage,
respectively. Our strain, as compared to the type strain, was resistant to erythromycin because of the presence of a
new erm 43 gene encoding a 23S rRNA N-6-methyltransferase in its genome which was not detected in the
reference strain. Interestingly, our patient received azithromycin 250 mg daily for bronchiolitis obliterans syndrome
for more than one year before the isolation of this bacterium.
Conclusions: Although significance of isolating this bacterium remains uncertain in terms of clinical evolution, this
bacterium could be considered as an opportunistic human pathogen as previously reported for other species in
this genus, especially in immunocompromised patients.
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Cystic fibrosis (CF) is one of the most common inherited
autosomal recessive disease in the Caucasian population.
It is due to mutations in the product of the gene encoding
the CF transmembrane conductance regulator (CFTR),
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reproduction in any medium, provided the orregulator gene [1]. Although CF is a multisystemic disease,
the clinical picture is generally dominated by pulmonary
involvement, the main cause of morbidity and mortality in
this disease. Lung disease is characterized by recurrent
and alternative cycles of airway infection and inflam-
mation, leading to bronchiectasis and subsequently to
respiratory failure where lung transplantation may consti-
tute the ultimate therapeutic option [2]. Infections in CF
patients are considered to be polymicrobial [3]. The pa-
thogens which are traditionally involved include Pseudo-
monas aeruginosa, Staphylococcus aureus, Haemophilusl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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studies have shown that the community of microbes
present in the airway of CF patients is more diverse and
complex than previously thought [3,8-10]. Many new,
emerging and/or multidrug resistant bacteria have been
recently reported in CF patients using different technolo-
gies including new culture media and molecular methods
[3,8,11,12]. In this study, we report the isolation and full
description of Microbacterium yannicii isolated from the
sputum sample from a lung transplanted CF adult patient
for which we have recently published the genome se-
quence [13]. Microbacterium yannicii G72T the reference
type strain isolated from surface sterilized roots of
Arabidopsis thaliana was used for comparison [14]. The
genus Microbacterium was first proposed in 1919 [15].
Microbacterium sp. belongs to the family Microbacteria-
ceae [16,17], order Actinomycetales, class Actinobacteria
[17] which comprises mainly aerobic Gram positive bac-
teria with high G+C content and a peptidoglycan defined
by a B-type cross linkage [18]. Based on phylogenetic pro-
perties and chemotaxonomic features, the genera Micro-
bacterium and Aureobacterium were unified to form the
redefined genus Microbacterium in 1998 [19]. From mid
1990s, the presence of Microbacterium was recognized in
human clinical specimens [20-22]. However, to the best of
our knowledge, bacteria of this genus have never been
reported in clinical samples from CF patients. Here, we
present a full description of phenotypic and genomic
properties of this new bacterium isolated from a CF spu-
tum sample.
Case report
A 23-year-old woman who has been lung transplanted
for CF (heterozygote delta F508/1717-1G genotype) was
admitted in emergency in November 2010 in our me-
dical department for acute respiratory failure in the
context of uncontrolled CF-related diabetes with keto-
acidosis coma. She required rapidly mechanical venti-
lation support, adapted metabolic adjustment, diabetes
management, and nutritional supporting care. Her med-
ical history included long term colonization by multi
drug resistant Pseudomonas aeruginosa and Burkhol-
deria multivorans. She had undergone bilateral lung
transplantation when she was 19 years old, and 2 years
later, she developed progressive chronic lung allograft
dysfunction (CLAD) with a bronchiolitis obliterans syn-
drome (BOS) stage 3 since the last 6 months and a
respiratory insufficiency requiring oxygen supplement
2 months before the admission. The immunosuppressive
regimen on admission consisted of tacrolimus (trough
level around 8 to 10 ng/ml), mycophenolate mofetil
(500 mg twice daily) and azithromycin 250 mg daily for
BOS for more than one year. The worsening of respi-
ratory function was associated with the persistence ofPseudomonas aeruginosa and Burkholderia multivorans
colonization along with appearance of Aspergillus fumi-
gatus. During hospitalization in the ICU, probabilistic
antibiotherapy consisted of an association of ceftazidime,
tobramycin and inhaled colistin. After an initial im-
provement, despite she still required oxygenotherapy de-
vice and intermittent noninvasive ventilation support,
her respiratory function worsened on January 2011. A
sputum sample was collected on January 7th, in which
multiresistant Pseudomonas aeruginosa and Burkhol-
deria multivorans were isolated on chocolate Poly ViteX
agar (bioMérieux, Marcy l’Etoile, France) and cepacia
agar (AES laboratory, Combourg, France), respectively.
An atypical gram positive strain was isolated at 105
CFU/ml on Columbia CNA agar plate. A treatment with
ceftazidime, temocillin and inhaled colistin was started
again. Her respiratory function continued to deteriorate
and she died after 2 months in a septic clinical condition.
Results
Phenotypic features
The gram positive strain was isolated on Columbia
colistin-nalidixic acid CNA agar with 5% sheep blood
(bioMérieux), after 24 hours of incubation at 37°C with
5% CO2 (Figure 1A,1B,1C). It also grew on COS me-
dium at 29°C after 24 hours. The colonies are 0.1-
0.2 mm in diameter. The isolate was an aerobic, yellow
pigmented (Figure 1A), rod-shaped, non-motile, oxidase
negative and catalase positive bacterium. This strain was
able to grow in microaerophillic atmosphere but not in
anaerobic atmosphere. It also grew very weakly at a salt
concentration of up to 10% after 48 hours of incubation.
As the spectrum for Microbacterium yannicii was not
available in the Bruker database at the time of our strain
isolation, we were not able to identify correctly and after
the addition of Microbacterium yannicii G72 type strain
spectrum in our local database, our strain was identified
as Microbacterium yannicii with a low score (Score 1.3).
Hence, we proceeded with 16SrRNA sequencing for
precise identification. Table 1 outlines the results of
the commercial phenotypic tests done which includes
apiCoryne, apiCH-50 and apiZYM (BioMerieux, Marcy
l’Etiole, France) tests to distinguish the CF clinical isolate
from five type strains of the genus Microbacterium in-
cluding Microbacterium yannicii G72T DSM 23203,
Microbacterium trichothecenolyticum DSM 8608, Micro-
bacterium flavescens DSM 20643 and Microbacterium
hominis DSM 12509. In apiZYM, the enzymatic reaction
for β-glucuronidase was positive for CF Microbacterium
yannicii PS01 as well as Microbacterium yannicii G72T
(DSM 23203). Although some of the biochemical tests
for our strain yielded results similar to those reported
for M. yannicii G72 type strain [14], however, we found
at least nine differences between our isolate and the type
Figure 1 Colonial morphology, gram staining and transmission electron microscopic image of the CF clinical isolate Microbacterium
yannicii PS01. A. CF clinical isolate Microbacterium yannicii PS01 was grown on Columbia colistin-nalidixic acid agar with 5% sheep blood
(bioMérieux) at 37°C with 5% CO2. The colony appeared as yellow, round and smooth. B. Gram staining picture of the gram-positive coccobacilli
CF clinical isolate “CF Microbacterium yannicii PS01” viewed at 100X magnification. C. Transmission electron microscopy image of M. yannicii strain
PS01, using a Morgani 268D (Philips) at an operating voltage of 60kV. The scale bar represents 900 nm.
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son to the three other type strains. Antibiotic suscepti-
bility was determined on Columbia agar with 5% sheep
blood (COS) (bioMérieux) as per CA-SFM guidelines for
Coryneform species. Table 2 shows the antibiotic suscep-
tibility pattern of these five strains. The CF clinical strain
was resistant to fosfomycin, erythromycin, clindamycin,
gentamicin, tobramycin, ciprofloxacin and ofloxacine.
The CF clinical isolate was also resistant to trimetho-
prim-sulfamethoxazole whereas M. yannicii G72 type
strain was not (Table 2).
Genotypic features
The 16S rRNA sequence of our isolate Strain PS01
showed 98.8% similarity with Microbacterium yannicii
G72T strain (DSM23203) (GenBank accession number
FN547412), 98.7% with Microbacterium trichotheceno-
lyticum, and 98.3% similarity with both Microbacterium
flavescens and Microbacterium hominis. Based on 16S
rRNA full length gene sequence (1510 bp), our isolate
was identified as Microbacterium yannicii. Partial rpoB
sequences (980 bp) as well as partial gyrB sequences
were also determined for the four strains and aconcatenated phylogenetic tree was constructed to show
the phylogenetic position of CF Microbacterium yannicii
PS01 (Figure 2).
Genome analysis and comparison
The genome of CF Microbacterium yannicii (Strain
PS01, CSUR Reference No.P191) was sequenced and the
draft genome sequence has been deposited in EMBL un-
der the accession number CAJF01000001-CAJF01000067
[13]. The genome exhibits a total size of 3,952,501 bp and
a G+C content of 69.5% (Table 3). We performed in silico
DNA - DNA hybridization of the whole genome of
CF Microbacterium yannicii against the two available
genomes in this genus i.e. Microbacterium testaceum
StLB037 and Microbacterium laevaniformans OR221 and
the overall results are presented in Table 3. At E-value
1.00e-5, the species coverage in Microbacterium testaceum
StLB037 and Microbacterium laevaniformans OR221 was
only 28% and 25.05%, respectively (Table 3). The numbers
of proteins with no similarity in comparison to CF
Microbacterium yannicii were 882 and 988 and with simi-
larity up to 80% were 598 and 580 of Microbacterium
testaceum StLB037 and Microbacterium laevaniformans
Table 1 Comparison of phenotypic characteristics of M. yannicii PS01 with closely related species
Characteristics CFM.yannicii M.yannicii M.trichothecenolyticum M.flavescens M.hominis
Colour of the colony Yellow Yellow Yellow Yellow White Yellow White
Motility No No No No No
Growth at 29°C Yes Yes Yes Yes Yes
Growth at 37°C Yes Yes Yes Yes Yes
CAT + + + + +
OXI - - - - -
apiZYM
Esterase lipase + + W+ W+ +
Cystine arylamidase W+ + W+ W+ W+
α-chymotrypsin - - + + -
Naphthol-AS-BI-phosphohydrolase - + + - -
β-glucuronidase + + - - -
α-fucosidase - + W+ - -
Assimilation of apiCH50
DARA - + - + -
RIB - + - - -
DXYL - + + + +
GAL - + + - +
RHA - - - + +
NAG - - W+ - +
MEL - + - - -
TRE + + - + +
INU + - - - -
AMD - + W+ - +
GLYG - + - - +
GEN - + - - +
DFUC + + - - -
Api CORYNE
Pyr A - - + + -
β GUR + + - - -
GEL + + - + -
Phenotypic characteristics Specific phenotypic characteristics of the CF isolate and comparison with closely related Microbacterium spp. Strain 1: M. yannicii DSM
23203, Strain 2: CF M. yannicii PS01, Strain 3: DSM 8608 M. trichothecenolyticum, Strain 4: DSM 20643 M. flavescens and Strain 5: DSM 12509 M.hominis.
Abbreviation List: + Positive; - Negative; W+ weakly positive; CAT-Catalase; OXI-Oxidase; DARA–D-Arabinose; RIB–Ribose; DXYL–D-Xylose; RHA–L-Rhamnose;
NAG–N-AcetylGlucosamine;MEL–D-Mellibiose; TRE–D-Trehalose; INU–Inulin; AMD–Amidon; GLYG–Glycogen; GEN–Gentiobiose; DFUC–D-Fucose; PYRA–Pyroglutamic
acid-β-naphthylamide; GUR–Naphthol ASBI-glucuronic acid; GEL–Gelatin (Strictly anaerobic); O–Negative control.
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of CF M. yannicii PS01 and found that there were 11
ORFs corresponding to Beta-lactamase family proteins, 5
ORFs corresponding to Aminoglycoside phosphotrans-
ferase family proteins that could explains the resistance of
this isolate to aminoglycosides, 1 ORF corresponding to a
macrolide efflux protein family and a new erm gene
encoding a 23S rRNA N-6-methyltransferase that could
explain the resistance to erythromycin (Table 2 and
Table 4). Microbacterium yannicii G72T reference strain
was susceptible to erythromycin and after designingprimers targeting the new erm gene we found that this ref-
erence strain do not contain this gene as PCR was only
positive for our CF isolate (data not shown). We also
found mutations in gyrA (Ser83Ala) and parC (Ser80Ala)
that were likely the cause of resistance against fluoro-
quinolone compounds (Table 2 and Table 4). Resistance
to trimethoprim-sulfamethoxazole was likely due to the
presence of a DHPS encoding gene (Table 4). We also
found 17 ORFs for multidrug efflux transporters such as
ion channels, multidrug ABC transporters, amino acid
transporters, and major facilitator superfamily proteins
Table 2 Antibiotic susceptibility testing of M. yannicii PS01 with closely related species
Antibiotic Abr. CF M.yannicii M.yannicii M.trichothecenolyticum M.flavescens M.hominis
Fosfomycin FOS50 7/R 7/R 7/R 7/R 7/R
Chloramphenicol C30 S S S 16/S 24/S
Doxycycline D30 S S S 7/R 7/R
Erythromycin E15 7/R S S 7/R 34/S
Vancomycin VA S S S 20/S 14/R
Clindamycin CM5 8/R S 12/R 7/R 7/R
Oxacillin OX5 20/S S 7/R 7/R 7/R
Rifampicin RA30 S S 24/S 28/S 20/S
Colistin CT50 30/S 20/S 20/S 12/R 10/R
Gentamicin GM15 12/R 10/R 14/R 7/R 10/R
Tobramycin TM10 7/R 7/R 7/R 7/R 7/R
Ciprofloxacine CIP5 7/R 15/R 12/R 7/R 20/S
Ofloxacine OFX5 7/R 11/R 10/R 7/R 7/R
Trimethoprim-Sulfamethoxazole SXT 7/R 31/S 24/S S S
Amoxicillin AX25 S S S S 20/S
Imipenem IMP10 S S S S S
Ceftazidime CAZ30 S 7/R 7/R 7/R 16/S
Ticarcilline TIC75 S S 7/R 7/R 12/R
Cefoxitin FOX30 S 20/S 7/R 16/S 26/S
Ceftriaxone CRO30 S S 24/S 7/R S
Amoxicillin-Clavulinic acid AMC30 S S S S S
Antibiotic susceptibility testing of CF clinical M. yannicii PS01 isolate and M. yannicii DSM 23203, M. flavescens, M. trichothecenolyticum and M. hominis
reference strains.
S sensitive, R resistant, Numbers given in mm.
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(Table 4).
Discussion
Genus Microbacterium belongs to the Microbacteriaceae
family, which contains species highly related by 16S
rRNA gene sequence that are difficult to identify at
the species level [19]. In this genus, the only available
genomes before our previous work [23] were those of
Microbacterium testaceum StLB037 and [23] and Mi-
crobacterium laevaniformans OR221 [24]. We used a
polyphasic taxonomic approach for the precise identifi-
cation of our new species. Firstly, MALDI-TOF-MS was
used for the identification of the bacterium. MALDI-
TOF-MS, a rapid and reliable method to identify bacter-
ial isolates at the species and subspecies level [25,26]
was used for the identification of this bacterium. Al-
though initially, our strain was only identified at the
genus level, it was correctly identified as Microbacterium
yannicii at the species level when spectrum from the ref-
erence strain was added to the database (Figure 3). We
performed apiZYM, apiCH50, apiCoryne and antibiotic
susceptibility phenotypic tests to compare our strain to
Microbacterium yannicii G72 type strain as well as toother closely related species (Microbacterium trichothe-
cenolyticum, Microbacterium flavescens and Microbacte-
rium hominis). In these tests, we have found only few
differences between our strain and the type strain. For
example we found that the reference strain was sus-
ceptible to erythromycin whereas our strain was not,
and this was likely due to the presence of a 23S rRNA
methyltransferase in the genome of our strain that was
absent in the reference strain. These differences may be
explained by the different lifestyle of the two strains, one
living in roots and the other in human respiratory tract
leading to different genomic repertoires that can pro-
duce alternative or atypical phenotypes that are better
adapted to their environment as recently exemplified
in Enterobacter aerogenes [27]. Finally, whole genome
sequence analysis of our strain allows us to fully cha-
racterize this new species including the genetic determi-
nants associated with its specific antibiotic resistance
phenotype likely acquired from different sources. In
silico DNA-DNA hybridization of the genome of CF
Microbacterium yannicii against the two other avail-
able genomes (Microbacterium testaceum StLB037 and
Microbacterium laevaniformans OR221) was very low
(≤ 70%). This was similar to DNA-DNA hybridization
Figure 2 Concatenated phylogenetic tree of Microbacterium species using NJ method. Concatenated phylogenetic tree based on 16SrRNA-
rpoB-gyrB sequence highlighting the phylogenetic position of CF Microbacterium yannicii PS01. Corynebacterium diphtheriae was used as an out
group. Sequences were aligned using CLUSTALX and Phylogenetic inferences obtained using Neighbor joining method within Mega 5 software.
Bootstrap values are expressed by percentage of 1000 replicates with Kimura 2 parameter test and shown at the branching points. The branches
of the tree are indicated by the genus and species name of the type strains followed by the NCBI Gene accession numbers: a: 16SrRNA; b: rpoB;
c: gyrB. (# rpoB and § gyrB sequence of M. trichothecenolyticum was obtained for this study).
Table 3 General features of M.yannicii PS01 genome in comparison with M. testaceum StLB037 and M. laevaniformans
OR221 genomes














M. yannicii PS01 CAJF01000001- CAJF01000067 α 3,952,501 69.54 3772 56 - - -
M. testaceum StLB037 AP012052 3,982,034 70.28 3795 58 1,106,788 (28%) 882 598
M. laevaniformans OR221 AJGR01000001- AJGR01000535 α 3,427,400 68.03 3294 72 989,933 (25.05%) 988 580
Table of comparison of M. yannicii PS01genome details in comparison with M. testaceum StLB037 and M. laevaniformans OR221 genomes.
α, genome sequences were deposited in Whole Genome Sequence (WGS), 67 contigs for M. yannicii and 535 contigs for M. laevaniformans;
β, the “In silico” DNA-DNA hybridization of M. yannicii PS01 genome against M. testaceum StLB037 and M. laevaniformans OR221 genomes, in parenthesis, the
percentage of coverage with respect to M. yannicii genome; Δ, Number of M. yannicii proteins with any similarity and with similarity up to 80%.
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Table 4 Antibiotic resistance genes in M.yannicii PS01 genome
Antibiotic class Gene name Size
(aa)





Beta-lactams ampC 323 Beta-lactamase class C Isoptericola variabilis 225 56.5 5.00E-114
ampC 422 Beta-lactamase class C Microbacterium testaceum
StLB037
54 1.00E-123
ampC 364 Beta-lactamase class C Paenibacillus mucilaginosus
KNP414
37.8 3.00E-59
ampC 338 Beta-lactamase class C Arthrobacter aurescens TC1 41.9 4.00E-67















penP 279 Beta-lactamase class A Microbacterium testaceum
StLB037
77.3 7.00E-146
- 615 Beta-lactamase domain protein Kribbella flavida DSM 17836 44.2 3.00E-148
- 626 Beta-lactamase domain protein Mycobacterium rhodesiae JS60 66.8 0





Aminoglycoside aph 51 Aminoglycoside phosphotransferase Microbacterium laevaniformans
OR221
72 2.00E-17





- 292 Aminoglycoside phosphotransferase Micromonospora lupini str.
Lupac 08
55.9 3.00E-95
- 308 Aminoglycoside phosphotransferase Streptosporangium roseum DSM
43021
43.8 7.00E-71
- 350 Aminoglycoside phosphotransferase Cellulomonas fimi ATCC 484 60.4 1.00E-125
Macrolides - 461 Macrolide-efflux protein Beutenbergia cavernae DSM
12333
65.4 2.00E-166
Fluoroquinolones gyrA mutated: S83A 883 DNA gyrase subunit A (EC 5.99.1.3) Microbacterium testaceum
StLB037
87.7 0
parC mutated: S80A 819 Topoisomerase IV subunit A (EC 5.99.1.-) Microbacterium testaceum
StLB037
82.7 0





corC 450 Magnesium and cobalt efflux protein Microbacterium testaceum
StLB037
78.4 0
kefA 373 Potassium efflux system Microbacterium laevaniformans
OR221
74.7 0
- 548 Putative MFS Superfamily multidrug
efflux transporter
Nocardia cyriacigeorgica GUH-2 72.8 0
- 513 putative efflux MFS permease Microbacterium laevaniformans
OR221
78.8 0
- 212 Putative threonine efflux protein Microbacterium testaceum
StLB037
61.6 1.00E-80





- 426 antibiotic efflux protein Microbacterium laevaniformans
OR221
83.5 0
- 526 probable multidrug resistance
transporter, MFS family
Cellulomonas fimi ATCC 484 68.8 0
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Table 4 Antibiotic resistance genes in M.yannicii PS01 genome (Continued)
- 474 Inner membrane component of
tripartite multidrug resistance system
Arthrobacter aurescens TC1 68.2 0










- 519 multidrug resistance protein Arthrobacter aurescens TC1 54.2 8.00E-177










- 303 ABC-type multidrug transport system,
ATPase component
Paenibacillus curdlanolyticus YK9 59.5 7.00E-110
- 273 ABC-type multidrug transport system,
permease component
Paenibacillus curdlanolyticus YK9 67.7 3.00E-121





General features of CF M. yannicii PS01 resistome showing the antibiotic resistance genes present and percentage of identity with best blast hit organism.
01 0 02 0 03 0 04 0 05 0 06 0 07 0 08 0 09 0 01 0 0 0
M i c r o b a c t e r i u m  k e t o s i r e d u c e n s  D S M  1 2 5 1 0 T  D S M
M i c r o b a c t e r i u m  t e r r a e  D S M  8 6 1 0 T  D S M
M i c r o b a c t e r i u m  f l a v e s c e n s  D S M  2 0 6 4 3 T  D S M
M i c r o b a c t e r i u m  t r i c h o t h e c e n o l y t i c u m  D S M  8 6 0 8 T  D S M
M i c r o b a c t e r i u m  s p  D S M  2 0 6 1 9  D S M
M i c r o b a c t e r i u m  a e r o l a t u m  D S M  1 4 2 1 7 T  D S M
M i c r o b a c t e r i u m  k e r a t a n o l y t i c u m  D S M  8 6 0 6 T  D S M
M i c r o b a c t e r i u m  p a l u d i c o l a  D S M  1 6 9 1 5 T  D S M
M i c r o b a c t e r i u m  s c h l e i f e r i  D S M  2 0 6 0 6  D S M
M i c r o b a c t e r i u m  a r b o r e s c e n s  D S M  2 0 7 5 4 T  D S M
M i c r o b a c t e r i u m  i m p e r i a l e  D S M  2 0 5 3 0 T  D S M
M i c r o b a c t e r i u m  t h a l a s s i u m  D S M  1 2 5 1 1 T  D S M
M i c r o b a c t e r i u m  t h a l a s s i u m  J C M  1 2 0 7 9 T  D S M
M i c r o b a c t e r i u m  u l m i  D S M  1 6 9 3 1 T  D S M
M i c r o b a c t e r i u m  k o r e e n s e  D S M  1 8 3 3 2 T  D S M
M i c r o b a c t e r i u m  r e s i s t e n s  D S M  1 1 9 8 6 T  D S M
M i c r o b a c t e r i u m  a u r u m  5 5  R L T
M i c r o b a c t e r i u m  a u r u m  D S M  8 6 0 0 T  D S M
M i c r o b a c t e r i u m  h o m i n i s  D S M  1 2 5 0 9 T  D S M
M i c r o b a c t e r i u m  l a e v a n i f o r m a n s  D S M  2 0 1 4 0 T  D S M
M i c r o b a c t e r i u m  t e r r e g e n s  D S M  2 0 4 4 9 T  D S M
M i c r o b a c t e r i u m  l a c t i c u m  D S M  2 0 1 7 2  D S M
M i c r o b a c t e r i u m  l a c t i c u m  I M E T  1 0 7 1 2 T  H K J
M i c r o b a c t e r i u m  l a c t i c u m  D S M  2 0 4 2 7 T  D S M
M i c r o b a c t e r i u m  d e x t r a n o l y t i c u m  D S M  8 6 0 7 T  D S M
M i c r o b a c t e r i u m  b a r k e r i  D S M  2 0 1 4 5 T  D S M
M i c r o b a c t e r i u m  f o l i o r u m  D S M  1 2 9 6 6 T  D S M
M i c r o b a c t e r i u m  h y d r o c a r b o n o x y d a n s  D S M  1 6 0 8 9 T  D S M
M i c r o b a c t e r i u m  p h y l l o s p h a e r a e  D S M  1 3 4 6 8 T  D S M
M i c r o b a c t e r i u m  s p  D S M  1 5 4 6 1  D S M
M i c r o b a c t e r i u m  n a t o r i e n s e  D S M  1 7 2 7 7 T  D S M
M i c r o b a c t e r i u m  l i q u e f a c i e n s  D S M  2 0 6 3 7  D S M
M i c r o b a c t e r i u m  l i q u e f a c i e n s  D S M  2 0 6 3 8 T  D S M
M i c r o b a c t e r i u m  l i q u e f a c i e n s  H K I  1 1 3 7 4  H K J
M i c r o b a c t e r i u m  m a r i t y p i c u m  D S M  1 2 5 1 2 T  D S M
M i c r o b a c t e r i u m  o x y d a n s  D S M  2 0 5 7 8 T  D S M
M i c r o b a c t e r i u m  l u t e o l u m  D S M  2 0 1 4 3 T  D S M
M i c r o b a c t e r i u m  s a p e r d a e  B 2 4 5  U F L
M i c r o b a c t e r i u m  s a p e r d a e  I M E T  1 1 0 7 6 T  H K J
A g r o c o c c u s  j e n e n s i s  D S M  9 5 8 0 T  D S M
M i c r o b a c t e r i u m  h a l o t o l e r a n s  D S M  1 5 8 5 5 T  D S M
M i c r o b a c t e r i u m  t e s t a c e u m  D S M  2 0 1 6 6 T  D S M
M i c r o b a c t e r i u m  t e s t a c e u m  D S M  2 0 5 2 6  D S M
M i c r o b a c t e r i u m  t e s t a c e u m  I M E T  1 0 3 6 1 T  H K J
C F  m i c r o b a c t e r i u m  y a n n i c i i
M i c r o b a c t e r i u m  y a n n i c i i  T
M i c r o m o n o s p o r a  s p  B 2 6 0  U F L
M i c r o b a c t e r i u m  s p  D S M  2 0 6 2 0  D S M
C o r y n e b a c t e r i u m  d i p h t h e r i a e  D S M  4 4 1 2 3 T  D S M
M i c r o b a c t e r i u m  o l e i v o r a n s  4 2 5  R L T
M i c r o b a c t e r i u m  o l e i v o r a n s  D S M  1 6 0 9 1 T  D S M
M i c r o b a c t e r i u m  s p  D S M  2 0 6 2 1  D S M
M i c r o c o c c u s  l u t e u s  I M E T  1 1 2 4 9  H K J
M S P  D e n d r o g r a m
D i s t a n c e  L e v e l
Figure 3 MSP Dendrogram based on different Microbacterium species hierarchy along with other species of the genus Microbacterium
(reference spectra obtained from Bruker database) upon the addition of Microbacterium yannicii G72 type strain and CF Microbacterium
yannicii PS01. (* Spectra generated).
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scription of Microbacterium yannicii G72T species by
Karojet et al. who showed a genetic relatedness of only
15.9%, 31.2%, and 45.1% between reference strain
Microbacterium yannicii G72 and Microbacterium ho-
minis, Microbacterium insulae, and Microbacterium
trichothecenolyticum, respectively [14]. As all the organ
transplant recipients, our patient was immunocom-
promised, with an over immunosuppressive regimen
containing a long macrolide therapy in the context of
chronic lung allograft dysfunction, such conditions with
might play a crucial role in the development of Micro-
bacterium spp. infection or colonization. Indeed Micro-
bacterium spp. have been described as a causative agent
of infections in immunocompromised patients such as,
cancer patients [28,29], endophthalmitis patients [21],
interstitial pulmonary infection after heart transplant-
ation [30], bone marrow transplant recipients [31], and
bacteremia [32-34]. To the best of our knowledge, such
infection with Microbacterium spp has not been previ-
ously described in the double context of lung trans-
plantation and in cystic fibrosis. Microbacterium spp.
have been isolated from clinical specimens including
blood culture, superficial wounds, pleural fluid, sinus
aspirate, bone infection, endophthalmitis, dialysis fluid,
lymph node, catheter tip, knee puncture fluid, wound
swab, urine, gall bladder, throat swab, prosthetic hip
infection, conjuctival swab, tracheal secretion and ure-
thral swab [35]. The source of this bacterium in our
patient was also undetermined but in our opinion,
plants or vegetables may be a potential source of trans-
mission in CF patients as well as a possible person to
person transmission from another patient. Bacteria of
the genus Burkholderia, Pandoraea, or Pseudomonas
for example, which are known to be frequently recov-
ered in the respiratory tract of CF patients, are also
endophytic bacteria in plants. There results reinforce
the hypothesis that plant associated environments may
act as niche for putative opportunistic human patho-
genic bacteria [36].
Conclusions
Our results showed that CF Microbacterium yannicii,
which has previously been isolated from Arabidopsis
thaliana roots, has never been reported from a human
clinical specimen and its pathogenicity in this context is
unknown. Studies have shown that bacteria from this
genus have been associated previously with infections,
predominantly in immunocompromised patients; how-
ever, the isolation of Microbacterium yannicii is unclear
if it could have been the result of a specific exacerbation
observed in this patient. In our study, the patient
received immunosuppressive therapy since her lung
transplantation. Because the patient was also chronicallycolonized by other well-known pathogens, it is difficult to
establish the true significance of isolating this bacterium
in terms of clinical evolution. Hence, it is hypothesized
that this bacterium could be considered as an opportunis-
tic human pathogen in immunocompromised patients but
this should be further investigated in the future.
Methods
Bacterial isolate and identification
Microbacterium yannicii G72T reference strain
(DSM23203) [14] was used as a control for the com-
parison of phenotypic and genotypic properties of our
strain. Our CF strain was isolated on Columbia CNA
agar plate (bioMérieux), and was identified by Matrix
assisted Laser desorption and ionization time-of-flight
mass spectrometry (MALDI TOF-MS) using a Mi-
croflex machine (Bruker Daltonics). The biochemical
tests were performed on the commercially available
apiCoryne, apiCH-50 and apiZYM test strips (BioMerieux,
Marcy l’Etiole, France) according to manufacturer’s
i0n1str0uctions.
Antibiotic susceptibility test
Antibiotic susceptibility was determined on Columbia
agar with 5% sheep blood (COS) (bioMérieux) by disk
diffusion method as per CA-SFM guidelines for coryne-
form species and the susceptibility results were interpre-
ted according to the recommendations of the “Comité
de l’Antibiogramme de la Société Française de Micro-
biologie (CA-SFM)” (www.sfm-microbiologie.org/).
PCR and sequencing
To investigate the phylogenetic position of this strain,
16S rRNA, rpoB and gyrB genes were amplified and se-
quenced with Big Dye Terminator reagents (Applied
Biosystems) ABI 3730 Automated Sequencer and the se-
quences were blasted against the GenBank database. The
sequence of the primers used in this study are 16SrRNA
F-5′-AGAGTTTGATCCTGGCTCAG-3′, 16SrRNA R-
5′-ACGGCTACCTTGTTACGACTT-3′, MY rpoB F-5′-
AAGGGMACSTTCGTCATCAA-3′, MY rpoB R-5′-CG
ATCAGACCGATGTTCGGG-3′, MYgyrB F-5′-GASSGC
STTCCTSAACAAGG-3′and MYgyrB R-5′-GCNCGGA
ASCCCTCYTCGTG-3′. Sequence alignment was per-
formed using CLUSTAL X, and concatenated phylo-
genetic tree was constructed using MEGA 5 software
(Molecular Evolutionary Genetic Analysis, vers.5, 2011)
using neighbor joining tree method and 1000 bootstrap
replications [37].
Genome
The genome of this strain was sequenced using Genome
Sequencer Titanium (454 Life Sciences, Branford, CT)
and reported recently [13]. All contigs from genome
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“RAST server: Rapid Annotation using Subsystems
Technology (http://www.theseed.org)” [38] to predict
protein-encoding genes, rRNA and tRNA sequences,
and assigned functions to these genes. Predicted proteins
were compared against Non Redundant (nr) GenBank
database using BLASTP (e-value 10E-8; identity ≥30%;
coverage ≥50%) and COG databases of the National
Center for Biotechnology Information (NCBI) (http://
www.ncbi.nlm.nih.gov). tRNA and rRNA genes were also
verified on tRNAscan-SE Search Server (http://lowelab.
ucsc.edu/tRNAscan-SE) and RFAM (http://rfam.sanger.
ac.uk) respectively. Genome comparison was performed
by “in silico” DNA-DNA hybridization using BlastN
analysis in a local bioserver to determine the full-length
alignment between two genome sequences and the cove-
rage percentage using the cut-off stringency of E-value
at 1.00e-5 [30].
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